World Health Organization. World health report. Geneva: World Health Organization; 2000.
Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–76.
Soler-Cataluña JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–31.
Katsura H. Economic evaluation of acute exacerbation of COPD. Respir Med 2004;5:324–329 (in Japanese).
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006: p. 64–5.
Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
Higashiyama Y, Watanabe A, Aoki N, Niki Y, Kono S. Clinical evaluation of levofloxacin versus oral β-lactams for acute exacerbation of COPD. Jpn J Chemother 2008;56:33–48 (in Japanese).
Andre-Alves MR, Jardim JR, Frare e Silva R, Fiss E, Freire DN, Teixeira PJ. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J Bras Pneumol. 2007;33:43–50.
Umut S, Tutluoglu B, Aydin Tosun G, Müsellim B, Erk M, Yildirim N, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. J Chemother. 1999;11:211–4.
Hisada T, Ishizuka T, Aoki H, Yanagitani N, Ono A, Imai H, et al. Clinical evaluation of garenoxacin on acute exacerbations of chronic obstructive pulmonary disease. J New Rem Clin 2009;58:1808–1820 (in Japanese).
D’Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2005;49:4035–41.
Koch CC, Esteban DJ, Chin AC, Olson ME, Read RR, Ceri H, et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46:19–26.
Amsden GW. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10–21.
Milstone AP. Use of azithromycin in the treatment of acute exacerbation of COPD. Int J Chronic Obstruct Pulm Dis. 2008;3:515–9.
Branthwaite A, Pechere JC. Pan-European survey of patients’ attitudes to antibiotics and antibiotic use. J Int Med Res. 1996;24:229–38.
Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious disease. Infect Agents Dis. 1994;3:266–73.
Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short-term antibiotic regimens. BMJ. 1987;295:814–8.
Colcher IS, Bass JW. Penicillin treatment of streptococcal pharyngitis: a comparison of schedules and the role of specific counseling. JAMA. 1972;222:657–9.
Pichicero ME. Short course antibiotic in acute otitis media and sinusitis infections. J Int Med Res. 1998;17:828–33.
Pichicero ME. Short course antibiotic therapy for respiratory infections: a review of the evidence. Pediatr Infect Dis J. 2000;19:929–37.
Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993;31(suppl E):65–71.
Bernstein JM. Treatment of community-acquired pneumonia—IDSA guidelines. Chest. 1999;115:9S–13S.
Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin N Am. 2004;18:761–76.
Inoue M, Farrell DJ, Kaneko K, Akizawa K, Fujita S, Kaku M, et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT year 1–5 (1994–2004). Microb Drug Resist. 2008;14:109–17.
Inoue M, Kaneko K, Akizawa K, Fujita S, Kaku M, Igari J, et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1–3 (1999–2002). J Infect Chemother. 2006;12:9–21.
Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–6.
Baldwin DR, Wise R, Andrews JW, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J. 1990;3:886–90.
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.